Can I Take Vitamin D with PT-141 (Bremelanotide)?

HealthRX.com

Vyleesi's label names no vitamin D interaction

Print or save as PDF

  • Interaction status / Vitamin D is not named in the Vyleesi Drug Interactions section or contraindications [1]
  • Label absorption warning / May slow gastric emptying and reduce absorption of oral medicines [1]
  • Vyleesi dose / 1.75 mg subcutaneously as needed, at least 45 minutes before activity [1]
  • Vyleesi approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Vitamin D forms / D3 (cholecalciferol) and D2 (ergocalciferol), sold as supplements [4]
  • Adult RDA / 600 IU/day ages 1 to 70; 800 IU/day from 71 [2]
  • Adult UL / 4,000 IU/day [3]

What product does the label cover?

PT-141 is another name for bremelanotide, but the FDA-approved product is Vyleesi, a 1.75 mg subcutaneous autoinjector used as needed at least 45 minutes before sexual activity, with no more than one dose in 24 hours and no more than 8 doses per month [1]. Vyleesi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not indicated for men, for postmenopausal women, or to enhance sexual performance [1]. Compounded or research-use PT-141 products are not Vyleesi and are not FDA-approved drugs [5][1].

What does the Vyleesi label say about oral medicines?

The Drug Interactions section carries two specific messages. It says Vyleesi may slow gastric emptying and reduce the rate and extent of absorption of concomitantly administered oral medicines. It says to avoid Vyleesi with oral drugs that depend on threshold concentrations for efficacy, such as antibiotics, and to consider skipping Vyleesi when a quick effect from an oral medicine such as indomethacin is wanted [1]. It also says Vyleesi may significantly decrease the systemic exposure of oral naltrexone, and that the pair should be avoided when naltrexone is taken for alcohol or opioid addiction [1]. Only naltrexone and indomethacin were meaningfully affected in the clinical pharmacology studies [1].

Does food timing matter for vitamin D?

In a 90-day randomized trial of 62 healthy older adults given a monthly 50,000 IU dose of vitamin D3, the 12-hour rise in vitamin D3 was larger with a low-fat meal than with a high-fat meal or no meal. However, 25-hydroxyvitamin D levels at 30 and 90 days did not differ between the three groups [7]. Dietary fat was not required to raise 25-hydroxyvitamin D in that trial [7].

What vitamin D dose is standard?

Vitamin D is a fat-soluble vitamin sold over the counter as D3 (cholecalciferol) and D2 (ergocalciferol), and it is also added to foods; the FDA Daily Value on supplement and food labels is 20 mcg (800 IU) [4][8]. The Institute of Medicine RDA is 600 IU/day for ages 1 to 70 and 800 IU/day from age 71, assuming minimal sun exposure [2]. The tolerable upper intake level for adults is 4,000 IU/day, a level above which the risk of adverse events rises and not a target intake [3]. Toxicity from vitamin D is rare and usually comes from very large doses; a 25-hydroxyvitamin D above 150 ng/mL (375 nmol/L) is the hallmark of toxicity from overdosing [9].

The Endocrine Society 2024 guideline suggests against routine 25-hydroxyvitamin D testing in people without an established indication for testing or treatment, and suggests against empiric supplementation above the dietary reference intake in healthy adults younger than 75 [4].

What should I watch for with Vyleesi?

The label's main safety issues are blood pressure and heart rate, focal hyperpigmentation, and nausea [1]. Each dose can transiently raise blood pressure and lower heart rate; the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute, usually back to baseline within 12 hours [1]. In an ambulatory study of 127 premenopausal women dosed once daily for 8 days, mean daytime increases were 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. The label says to consider the patient's cardiovascular risk before starting and periodically during treatment and to ensure blood pressure is well controlled, and it contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease [1].

Nausea occurred in 40.0% of Vyleesi-treated patients versus 1.3% on placebo; 13% received an anti-nausea medicine and 8% stopped because of it [1]. Focal hyperpigmentation occurred in 1% of patients who received up to 8 doses per month versus none on placebo [1]. Flushing occurred in 20.3% versus 0.3%, injection site reactions in 13.2% versus 8.4%, and headache in 11.3% versus 1.9% [1].

Bottom line

The Vyleesi label names no vitamin D interaction. Its general caution is that it may slow gastric emptying and reduce absorption of oral medicines [1]. Vitamin D intake follows the age-based RDA and the 4,000 IU/day adult upper limit [2][3].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, for whom is Vyleesi approved?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Questions worth asking

Choose the questions you want to keep

How much vitamin D do I need each day?
The Institute of Medicine RDA is 600 IU/day for ages 1 to 70 and 800 IU/day from age 71, with an adult upper limit of 4,000 IU/day [2][3].
Does vitamin D need to be taken with a fatty meal?
In a randomized trial of 62 healthy older adults given a monthly 50,000 IU dose of vitamin D3, 25-hydroxyvitamin D levels at 30 and 90 days did not differ between a high-fat meal, a low-fat meal and no meal [7].
Can Vyleesi change the absorption of oral medicines?
The label says Vyleesi may slow gastric emptying and reduce the rate and extent of absorption of oral medicines. It names oral drugs that depend on threshold concentrations, such as antibiotics, and drugs where a quick onset is wanted, such as indomethacin [1]. Only naltrexone and indomethacin were meaningfully affected in the clinical pharmacology studies [1].
Which conditions rule out Vyleesi?
The Vyleesi label lists uncontrolled hypertension and known cardiovascular disease as contraindications and says the drug is not recommended in patients at high risk for cardiovascular disease [1].
Show all 9 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-8.
  3. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - PMC.
  4. Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947.
  5. Official web page.
  6. U.S. National Library of Medicine, DailyMed. Ergocalciferol capsules (Rx) prescribing information. Ergocalciferol capsules (Rx) label
  7. Dawson-Hughes B, Harris SS, Palermo NJ, Ceglia L, Rasmussen H. Meal conditions affect the absorption of supplemental vitamin D3 but not the plasma 25-hydroxyvitamin D response to supplementation. J Bone Miner Res. 2013;28(8):1778-83.
  8. Daily Value on the Nutrition and Supplement Facts Labels | FDA.
  9. Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, Płudowski P, Jones G. Vitamin D Toxicity-A Clinical Perspective. Front Endocrinol (Lausanne). 2018;9:550.
PT-141 vitamin D interaction: evidence summary chart
Image: HealthRX.com. Full PT-141 vitamin D interaction guide and sources at healthrx.com/supplements-pt-141.